Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study.

Lisa M HessYongmei ChenPaolo B AbadaHeiko KonigRichard A Walgren

Published in: Advances in hematology (2022)

This study demonstrates the poor outcomes experienced by patients after cBTKi therapy. There is an urgent need for safe and effective treatments for patients with recurrent or progressive MCL.

Keyphrases

end stage renal disease
multiple sclerosis
ejection fraction
chronic kidney disease
stem cells
metabolic syndrome
adipose tissue
patient reported outcomes
cell therapy
insulin resistance